
In a study published by the BMJ a few years ago, it was found that antibiotics were prescribed in 60% …

AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints …

Biogen is one those companies, like Sanofi until its recent Bioverativ acquisition, that has real pressure to make a big …

Senescent cells are the dormant state that cells shift to in response to certain stressors, it is thought that they …

There has been another drug failure in a large Phase 3 that once again crushes a hope for a possible …

The latest data from GW Pharma is about as conclusively positive as you can usually hope to get with a …

It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on …

Biogen received marketing approval from the European Commission for Spinraza (nusinersen), its treatment for spinal muscular atrophy (SMA), in May …

On 18 December 2017, the District of New Jersey filed a complaint against Dr. Reddy’s Laboratories for failing to comply …

Sanofi interest in making a big acquisition has been clear for the last few years and its struggles to solidify …

Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …

Although those in pharma often dislike any references to drugs competing with each other for market as in a ‘race’, …

Following on from this week’s earlier piece on real world evidence, Jacqueline Corrigan-Curay, Director of CDER’s Office of Medical Policy at the FDA, …

NICE rejected Janssen’s Darzalex (Daratumumab) back in March last year, concluding that it wasn’t able to accurately determine the efficacy …

For women, possessing a mutated BRCA1 or BRCA2 gene significantly increases the chances of developing breast or ovarian cancer; at …